Regenxbio (RGNX) Misses Q1 EPS by 38c, Misses on Revenue

Regenxbio (NASDAQ: RGNX) reported Q1 EPS of ($1.72), $0.38 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $6.39 million versus the consensus estimate of $25.8 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Empire Petroleum (EP) files $150M mixed shelf
• First Carolina Financial Services CFO to retire in January 2027